(Q39624458)

13 September 2017

title

Over-expression of MDR1 in amrubicinol-resistant lung cancer cells (English)

1 reference

13 September 2017

Osamu Takakuwa

1

1 reference

13 September 2017

Tetsuya Oguri

2

1 reference

13 September 2017

Hiroaki Ozasa

3

1 reference

13 September 2017

Takehiro Uemura

4

1 reference

13 September 2017

Daishi Kasai

5

1 reference

13 September 2017

Mikinori Miyazaki

6

1 reference

13 September 2017

Ken Maeno

7

1 reference

13 September 2017

Shigeki Sato

8

1 reference

13 September 2017

publication date

3 December 2010

1 reference

Cancer Chemotherapy and Pharmacology

13 September 2017

published in

1 reference

13 September 2017

volume

68

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

669-676

1 reference

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Comparative activity of doxorubicin and its major metabolite, doxorubicinol, on V79/AP4 fibroblasts: a morphofunctional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Amrubicin for non-small-cell lung cancer and small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Immunohistochemical localization of carbonyl reductase in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

MDR1 gene expression in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1533-4

10.1007/S00280-010-1533-4

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference